Obesity and type 2 diabetes: What can be unified and what needs to be individualized?

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 6, 2011, Pages 1654-1663

  Eckel, Robert H ^a   Kahn, Steven E ^b   Ferrannini, Ele ^c   Goldfine, Allison B ^d   Nathan, David M ^e   Schwartz, Michael W ^f   Smith, Robert J ^g   Smith, Steven R ^h  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g BROWN UNIVERSITY   (United States)

^h FLORIDA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; AMFEBUTAMONE PLUS NALTREXONE; DEXFENFLURAMINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FENFLURAMINE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; LORCASERIN; METFORMIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PHENYLPROPANOLAMINE; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN;

AMNESIA; BARIATRIC SURGERY; BEHAVIOR CHANGE; BLOOD PRESSURE; BODY WEIGHT; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; COMORBIDITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DEPRESSION; DISEASE ASSOCIATION; DRUG TOLERABILITY; ENERGY BALANCE; GENETIC ASSOCIATION; GENETIC RISK; GLYCEMIC CONTROL; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID STORAGE; LIVER INJURY; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PANCREATITIS; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REMISSION; SEIZURE; SIDE EFFECT; STROKE; SUICIDAL IDEATION; VALVULAR HEART DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY; WEIGHT LOSS;

EID: 79956298859     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2011-0585     Document Type: Conference Paper

References (50)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
2. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010;8:29
3. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991;14:1132-1143
4. Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans.NEngl J Med 2009; 360:1509-1517
5. Frontini A, Cinti S. Distribution and development of brown adipocytes in the murine and human adipose organ. Cell Metab 2010; 11:253-256
6. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci 2010;1212:E1-E19
7. Larson-Meyer DE, Newcomer BR, Ravussin E, et al. Intrahepatic and intramyocellular lipids are determinants of insulin resistance in prepubertal children. Diabetologia 2011;54:869-875
8. Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes 2010;17:446-452
9. Bagdade JD, Bierman EL, PorteDJr. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 1967;46:1549-1557
10. Polonsky KS, Given BD, Hirsch L, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 1988;81:435-441 (Pubitemid 18075237)
11. Klöppel G, Löhr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985;4:110-125
12. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110 (Pubitemid 36042113)
13. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-846 (Pubitemid 46024990)
14. Johnson JD, Ahmed NT, Luciani DS, et al. Increased islet apoptosis in Pdx1+/- mice. J Clin Invest 2003;111:1147-1160 (Pubitemid 36519932)
15. Leibowitz G, Ferber S, Apelqvist A, et al. IPF1/PDX1 deficiency and β-cell dysfunction in Psammomys obesus, an animal with type 2 diabetes. Diabetes 2001;50:1799-1806
16. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997;17: 138-139
17. Rampersaud E, Damcott CM, Fu M, et al. Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes 2007;56:3053-3062 (Pubitemid 350223642)
18. Hayes MG, Pluzhnikov A, Miyake K, et al. Identification of type 2 diabetes genes in Mexican Americans through genome-wide association studies. Diabetes 2007;56:3033-3044 (Pubitemid 350223640)
19. Scherag A, Dina C, Hinney A, et al. Two new loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and German study groups. PLoS Genet 2010;6:e1000916
20. Lindgren CM, Heid IM, Randall JC, et al.; Wellcome Trust Case Control Consortium; Procardis Consortia; Giant Consortium. Genome-wide association scan meta-analysis identifies three loci influencing adiposity and fat distribution. PLoS Genet 2009;5: e1000508
21. Bogardus C. Missing heritability and GWAS utility. Obesity (Silver Spring) 2009;17:209-210
22. Lander ES. Initial impact of the sequencing of the human genome. Nature 2011;470:187-197
23. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008;8:923-934
24. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808 (Pubitemid 38063703)
25. Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002;8:1376-1382 (Pubitemid 36019422)
26. Thaler JP, Schwartz MW. Minireview: Inflammation and obesity pathogenesis: the hypothalamus heats up. Endocrinology 2010;151: 4109-4115
27. Calegari VC, Torsoni AS, Vanzela EC, et al. Inflammation of the hypothalamus leads to defective pancreatic islet function. J Biol Chem. 21 January 2011 [Epub ahead of print]
28. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403 (Pubitemid 34437694)
29. Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010;170:1566-1575
30. Larsen TM, Dalskov SM, van Baak M, et al.; Diet, Obesity, and Genes (Diogenes) Project. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med 2010; 363:2102-2113
31. Papadaki A, Linardakis M, Larsen TM, et al.; DiOGenes Study Group. The effect of protein and glycemic index on children's body composition: the DiOGenes randomized study. Pediatrics 2010; 126:e1143-e1152
32. Sjöström L, Lindroos AK, Peltonen M, et al.; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683-2693
33. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-761 (Pubitemid 47295642)
34. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248-256.e5
35. Sjöström L, Narbro K, Sjöström CD, et al.; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-752 (Pubitemid 47295641)
36. Makary MA, Clarke JM, Shore AD, et al. Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery. Arch Surg 2010;145:726-731
37. Vetter ML, Cardillo S, Rickels MR, Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 2009;150:94-103
38. Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 2009;33:786-795
39. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238:467-484; discussion 84-85
40. Lautz D, Halperin F, Goebel-Fabbri A, Goldfine AB. The great debate: medicine or surgery: what is best for the patient with type 2 diabetes? Diabetes Care 2011;34:763-770
41. Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med 2002;346:506-512 (Pubitemid 34441743)
42. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
43. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443 (Pubitemid 44903747)
44. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 2010;95:1566-1574
45. Eckel RH. Clinical practice. Nonsurgical management of obesity in adults. N Engl J Med 2008;358:1941-1950
46. Shai I, Jiang R, Manson JE, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care 2006;29:1585-1590 (Pubitemid 44127585)
47. Gálvez BG, San Martín N, Rodríguez C. TNF-α is required for the attraction of mesenchymal precursors to white adipose tissue in ob/ob mice. PLoS ONE 2009;4:e4444
48. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest 2007;117:2362-2368 (Pubitemid 47494333)
49. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115
50. Ryan DH, Johnson WD, Myers VH, et al. Nonsurgical weight loss for extreme obesity in primary care settings: results of the Louisiana Obese Subjects Study. Arch Intern Med 2010;170:146-154